News from ICAAC 2013: side effects
Several presenters at the 53rd ICAAC reported on treatment regimens and drugs that show good viral suppression with reduced side effects.
Crofelemer, a licensed treatment for noninfectious diarrohea in people on antiretrovirals, was found to be effective against 'sever, intransigent' diarrhoea and protease inhibitor (PI)-related diarrhea in a a placebo controlled trial.
Trial of new GSK drug
Analysis of eight studies found that GlaxoSMithKline's integrase inhibitor GSK1265744 is well tolerated with few serious adverse events. The studies, of 245 people taking either injected or oral treatment, found few serious lab abnormalities.
The most frequent adverse event, reactions around the injection site, were mild. Only 2.4% of participants withdrew from the trials due to adverse events and only two of these were considered to be drug-related.
Good Safety Profile With Long-Acting Integrase Inhibitor NATAP report
Switching drugs improves bone and kidney markers
Switching from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), (both with atazanavir/ritonavir), maintained viral suppression without showing adverse effects on markers for bone and kidney function in the ASSURE trial. Earlier studies had not shown such promising results, but the ASSURE trial enrolled people with a lower viral load (>75 copies).
TDF/FTC-to-ABC/3TC Switch Maintains Viral Suppression, Eases Bone Markers NATAP report
Successful interferon-based therapy for people with HIV and hepatitis C (HCV) coinfection leads to significant reductions in liver disease, liver related mortality and HIV progression, according to a Spanish study.
People with HIV/HCV coinfection do not generally respond as well to interferon-based therapy than people who only have HCV, and newer treatment regimens are based on triple therapy that includes HCV protease inhibitors, which has good cure rates and is easier to tolerate.More News
This page was published on 20 September, 2013
All content contained within this website is copyright © AFAO, unless otherwise stated. Content may be reproduced for non-commercial, personal research or educational purposes free of charge, provided the following citation is made: "Reprinted from [name of publication], published by the Australian Federation of AIDS Organisations". Contact AFAO regarding other uses of content.